Cargando…

CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma

Intrahepatic cholangiocarcinoma (ICC) is highly invasive and carries high mortality due to limited therapeutic strategies. In other solid tumors, immune checkpoint inhibitors (ICIs) target cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD1), and the PD1 ligand PD-L1 has...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Xiao-Jun, Lu, Jia-Cheng, Zeng, Hai-Ying, Zhou, Rong, Sun, Qi-Man, Yang, Guo-Huan, Pei, Yan-Zi, Meng, Xian-Long, Shen, Ying-Hao, Zhang, Peng-Fei, Cai, Jia-Bin, Huang, Pei-Xin, Ke, Ai-Wu, Shi, Ying-Hong, Zhou, Jian, Fan, Jia, Chen, Yi, Yang, Liu-Xiao, Shi, Guo-Ming, Huang, Xiao-Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435712/ https://www.ncbi.nlm.nih.gov/pubmed/34526987 http://dx.doi.org/10.3389/fimmu.2021.705378

Ejemplares similares

Distinct PD-L1/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors
por: Lu, Jia-Cheng, et al.
Publicado: (2019)

The clinical implications and molecular features of intrahepatic cholangiocarcinoma with perineural invasion
por: Meng, Xian-Long, et al.
Publicado: (2022)

KRAS acting through ERK signaling stabilizes PD-L1 via inhibiting autophagy pathway in intrahepatic cholangiocarcinoma
por: Gao, Zheng, et al.
Publicado: (2022)

Reprogramming Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD1 Therapy
por: Chen, Jiang, et al.
Publicado: (2023)

Prognostic Significance of Capn4 Overexpression in Intrahepatic Cholangiocarcinoma
por: Zhang, Chi, et al.
Publicado: (2013)

PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma
por: Fontugne, Jacqueline, et al.
Publicado: (2017)

Comparison analysis of PD-1/PD-L1 inhibitors plus lenvatinib or gemcitabine/cisplatin as first-line treatment for patients with advanced intrahepatic cholangiocarcinoma
por: Huang, Jia-Xin, et al.
Publicado: (2023)

LAG3-PD1 or CTLA4-PD1 Inhibition in Advanced Melanoma: Indirect Cross Comparisons of the CheckMate-067 and RELATIVITY-047 Trials
por: Zhao, Bai-Wei, et al.
Publicado: (2022)

Relationship between PD-L1 expression, CD8+ T-cell infiltration and prognosis in intrahepatic cholangiocarcinoma patients
por: Deng, Min, et al.
Publicado: (2021)

Lenvatinib Combined With a PD-1 Inhibitor as Effective Therapy for Advanced Intrahepatic Cholangiocarcinoma
por: Xie, Lulu, et al.
Publicado: (2022)

PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome
por: Tian, Lingyu, et al.
Publicado: (2020)

HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1
por: Jing, Chu-Yu, et al.
Publicado: (2019)

Successful treatment of stage IIIB intrahepatic cholangiocarcinoma using neoadjuvant therapy with the PD-1 inhibitor camrelizumab: A case report
por: Zhu, Shu-Guang, et al.
Publicado: (2022)

Inflammation-Based Scores Predict Responses to PD-1 Inhibitor Treatment in Intrahepatic Cholangiocarcinoma
por: Yang, Zhenyun, et al.
Publicado: (2022)

Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade
por: Ju, Fei, et al.
Publicado: (2022)

Clinicopathological and Prognostic Significance of Immunoscore and PD-L1 in Intrahepatic Cholangiocarcinoma
por: Wu, Hong, et al.
Publicado: (2021)

Machine learning: an approach to preoperatively predict PD-1/PD-L1 expression and outcome in intrahepatic cholangiocarcinoma using MRI biomarkers
por: Zhang, Jun, et al.
Publicado: (2020)

PGAM1 Inhibition Promotes HCC Ferroptosis and Synergizes with Anti‐PD‐1 Immunotherapy
por: Zheng, Yimin, et al.
Publicado: (2023)

Comprehensive Multiple Molecular Profile of Epithelial Mesenchymal Transition in Intrahepatic Cholangiocarcinoma Patients
por: Huang, Xiao-Yong, et al.
Publicado: (2014)

PD-1 blockade and radiotherapy combination for advanced Epstein-Barr virus-associated intrahepatic cholangiocarcinoma: a case report and literature review
por: Liao, Chun-Xu, et al.
Publicado: (2023)

Amplification of spatially isolated adenosine pathway by tumor–macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma
por: Lu, Jia-Cheng, et al.
Publicado: (2021)

A pan-cancer study of PD-1 and CTLA-4 as therapeutic targets
por: Cai, Zongqiang, et al.
Publicado: (2021)

PD-1 Inhibitors Plus Capecitabine as Maintenance Therapy for Advanced Intrahepatic Cholangiocarcinoma: A Case Report and Review of Literature
por: Wang, Zhihong, et al.
Publicado: (2021)

SIRPα and PD1 expression on tumor-associated macrophage predict prognosis of intrahepatic cholangiocarcinoma
por: Yang, Hui, et al.
Publicado: (2022)

Clinical significance of PD-1/PD-Ls gene amplification and overexpression in patients with hepatocellular carcinoma
por: Ma, Li-Jie, et al.
Publicado: (2018)

Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses
por: Chen, Xi, et al.
Publicado: (2020)

High level of CD73 predicts poor prognosis of intrahepatic cholangiocarcinoma
por: Xu, Ya-ping, et al.
Publicado: (2021)

Patient-Derived Xenograft Models for Intrahepatic Cholangiocarcinoma and Their Application in Guiding Personalized Medicine
por: Gao, Yang, et al.
Publicado: (2021)

Contrast-enhanced ultrasound in association with serum biomarkers for differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and intrahepatic cholangiocarcinoma
por: Yang, Jie, et al.
Publicado: (2020)

Protein tyrosine phosphatase PTP4A1 promotes proliferation and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma via the PI3K/AKT pathway
por: Liu, Long-Zi, et al.
Publicado: (2016)

A New Preoperative Prognostic System Combining CRP and CA199 For Patients with Intrahepatic Cholangiocarcinoma
por: Zheng, Bo-Hao, et al.
Publicado: (2017)

Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis
por: Huang, Shuang, et al.
Publicado: (2023)

The CTLA-4 and PD-1/PD-L1 Inhibitory Pathways Independently Regulate Host Resistance to Plasmodium-induced Acute Immune Pathology
por: Hafalla, Julius Clemence R., et al.
Publicado: (2012)

Real‐world utilization of PD‐1/PD‐L1 inhibitors with palliative radiotherapy in patients with metastatic non‐small cell lung cancer
por: Zhou, Zi‐Chao, et al.
Publicado: (2022)

Neddylation pathway is up-regulated in human intrahepatic cholangiocarcinoma and serves as a potential therapeutic target
por: Gao, Qiang, et al.
Publicado: (2014)

Prognostic Value and Predication Model of Microvascular Invasion in Patients with Intrahepatic Cholangiocarcinoma
por: Tang, Zheng, et al.
Publicado: (2019)

Upregulation of B7-H4 promotes tumor progression of intrahepatic cholangiocarcinoma
por: Xie, Nan, et al.
Publicado: (2017)

Anti-PD-1 Immunotherapy and Radiotherapy for Stage IV Intrahepatic Cholangiocarcinoma: A Case Report
por: Liu, Ze-Long, et al.
Publicado: (2020)

Efficacy and safety of PD-1/PD-L1 plus CTLA-4 antibodies ± other therapies in lung cancer: a systematic review and meta-analysis
por: Shen, Xiang, et al.
Publicado: (2023)

Proteome Landscapes of Human Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
por: Yi, Xiao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fi3ia84h3dl69mkkdsshdbav86